ETX-929 / Ensem Therap - LARVOL DELTA

ETX-929, a potential best-In-class, oral, highly potent and selective dual ON / OFF state Pan-KRAS small molecule inhibitor for the treatment of KRAS mutant and wild-type amplified cancers (AACR 2026) - "ETX-929 also shows good cross-species pharmacokinetics including higher species, excellent pre-clinical tolerability, and no meaningful off-target activity or in vitro safety signals, supporting its advancement toward clinical development. Overall, ETX-929 is a potential best-in-class, pan-KRAS inhibitor with superior potency, selectivity over NRAS / HRAS, excellent efficacy and favorable drug-like properties that could improve outcomes for KRAS-driven cancers that currently lack targeted therapeutic options."

Colorectal Cancer • Lung Cancer • Oncology • Solid Tumor • HRAS • KRAS • NRAS